Pharmaceutical industry news

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

Novartis Suffers Third Clinical Setback in a Week, Wiping Out Over $40 Billion in U.S. Market Value in a Single Day

Why a cannabis business is betting on dogs to reach FDA approval

Calling campus home

Medicaid/CHIP Monthly Enrollment Tracker

New Cancer Care Technology at Intermountain St. Mary’s Hospital Improves Precision & Comfort for Patients in Western Colorado

More opportunity. Fewer cars.

Carlsbad Man Now Back to Baseball After Prostate Cancer

How Northern Ireland can save almost 6,000 lives from cancer

Pneumococcal vaccination for older adults and for individuals in a clinical risk group: for healthcare practitioners

Information for healthcare practitioners on delivering the pneumococcal vaccination programme for ol...

House advances Carter’s bipartisan bill to reduce animal testing in drug development

Maharashtra FDA Enforces Zero Tolerance with Major Food Safety Crackdown

Septembre en or : lancement de deux nouveaux programmes de recherche dédiés aux cancers pédiatriques

Nuevos proyectos de consulta para la opinión pública

Septembre en or : 10 ans d’avancées scientifiques au service des enfants atteints de cancer

Freshers urged to get MenB vaccine as students arrive in Glasgow

Only known woolly dog pelt returns close to home and for the first time to Canada

Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons

Green shoots for UK pharma investment, but delivery will decide whether they take root

ICON taps Anthropic’s Claude to bring agentic AI to clinical trials

Growth-rate coordination across the width of a leaf preserves its flatness

Discovery Stack Pilot demonstrates the feasibility and outcomes of a scientist-designed peer-review model that separates quality and impact

The distribution of fitness effects of nonsynonymous mutations varies phylogenetically across animals

Seaweed carbon removal cannot keep up with climate-driven loss

The internet’s favorite cat comes to Apple Arcade with Pusheen’s Place

Qualität statt Quantität: Neue Erkenntnisse zur Rolle bestimmter CAR-T-Zellen in der Krebstherapie

Ionis Pharmaceuticals gets $85 price target des...

X4 Pharma Gains FDA Agreement to Cut Phase 3 Trial Size to 76 Patients

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, 2025 to 2026

MRSA, MSSA, Gram-negative bacteraemia infections by organisation and location of onset, and Clostrid...

Wegovy for Overweight Young Children: Novo Nordisk’s Obesity Drug Shows Effectiveness

Impact & Sustainability Report 2025: what EUR achieved

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Uncovering how a key RNA works sheds light on one of the major challenges in modern biology

The PPWR mandate: Essential strategies for pharma and medtech

Liver cancer patients appear to be living longer in a Can-Fite trial

Vor Biopharma (VOR) Completes Enrollment in Phase 3 Trial as Market Eyes Growth Potential

Enregistrement des antibiotiques dans VAMREG : e-learning pour les vétérinaires

Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints

XFOR Gains FDA Nod for Reduced Trial Size in Pivotal Phase 3 Study

Optimizing tomato plant growth with microbes

insitro Appoints Hideo Makimura as Chief Medical Officer to Lead Its Transition to a Clinical-Stage Company

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

BioVie Announces Next Stage of FDA Engagement for Phase 3 Parkinson’s Disease Program Evaluating Bezisterim

Artiva Biotherapeutics Announces Planned 2026 Data Readouts and Phase 3 Trial Initiation for AlloNK in Refractory Rheumatoid Arthritis

Nature Medicine features a BriaCell trial among 11 shaping medicine in 2026

BioVie seeks FDA feedback on a proposed Parkinson’s trial of about 175 patients.

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Oncologists say newly approved pancreatic cancer drug is a breakthrough for treatment

OKYO Pharma (NASDAQ: OKYO) readies Phase 3 trial of eye-pain drug urcosimod

A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial

A new trial for eye-related muscle weakness is planned for 2027. Vor Bio finished enrolling another.

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Climate policy does not start with the individual, but with society

Henry Schein to Participate in Upcoming Investor Conference in September

Gut infections can train the brain’s immune defences

Vaccine update

Vaccination newsletter for health professionals and immunisation practitioners.

Vaccine update: issue 375, Flu Special 2026

Latest developments in vaccines, vaccination policies and procedures for immunisation practitioners.